Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease
Phase of Trial: Phase IV
Latest Information Update: 15 May 2017
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Expanded access
- Sponsors Takeda
- 09 Jan 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 Planned initiation date changed from 1 Nov 2016 to 1 Aug 2016.
- 15 Nov 2016 Planned initiation date changed from 1 Aug 2016 to 1 Nov 2016.